Commentary

Video

Dr Garrido-Castro on Sacituzumab Govitecan With or Without Pembrolizumab in Metastatic HR+/HER2– Breast Cancer

Author(s):

Ana Christina Garrido-Castro, MD
Conference|ASCO Annual Meeting

Ana Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.

Ana Christina Garrido-Castro, MD, medical oncologist, co-director, Triple-Negative Breast Cancer Working Group, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses findings from the phase 2 SACI-IO HR+ trial (NCT04448886) evaluating sacituzumab govitecan-hziy (Trodelvy) with or without pembrolizumab (Keytruda) in patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Paolo Tarantino, MD, of Dana-Farber Cancer Institute
July 24th 2024

Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Adrienne G. Waks, MD
July 24th 2024

Tucatinib Retains its Role in HER2+ Metastatic Breast Cancer, Prompting Questions of T-DXd’s Potential Takeover in the First Line

Andrew J. Wagner, MD, PhD, medical director, Ambulatory Oncology, senior physician, Dana-Faber Cancer Institute; associate professor, medicine, Harvard Medical School
March 28th 2024

Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa

Paolo Tarantino, MD
July 23rd 2024

DESTINY-Breast03 and DESTINY-Breast06 Data Shape Metastatic Breast Cancer Treatment

Adrienne G. Waks, MD, of Dana-Farber Cancer Institute
July 23rd 2024

Neoadjuvant Therapy Selection: Are Abbreviated Regimens an Option in HER2+ Breast Cancer?